跳至主要内容
临床试验/NCT05202808
NCT05202808已完成不适用

RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

RxSight, Inc.27 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2021年12月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
RxSight, Inc.
入组人数
500
试验地点
27
主要终点
Absolute Manifest Refraction Spherical Equivalent (MRSE) Compared Between the Two Study Groups, LAL and Control

研究概览

简要总结

The primary objective of this study is to conduct a post-approval study which compares the LAL to a monofocal control IOL for safety outcomes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must sign a written Informed Consent form and be willing to undergo cataract surgery for the implantation of an IOL with random assignment to either the RxSight LAL or the monofocal control IOL.
  • Between the ages of 40 and 80 inclusive on the day the cataract surgery is performed.
  • Willing and able to comply with the requirements for study specific procedures and visits.
  • Able to complete a written questionnaire in English.

排除标准

  • Pre-existing macular disease in either eye.
  • Patients with sufficiently dense cataracts that preclude examination of the macula in either eye.
  • History of uveitis in either eye.
  • Evidence of ectasia in either eye.
  • Previous intraocular surgery in either eye. Eyes with previous pterygium excision are permitted as long as the pterygium did not extend more than 2mm onto the cornea from the limbus.
  • Subjects taking systemic medication that may increase sensitivity to UV light.
  • Subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen.
  • History of ocular herpes simplex virus in either eye.

结局指标

主要结局

Absolute Manifest Refraction Spherical Equivalent (MRSE) Compared Between the Two Study Groups, LAL and Control

时间窗: Postop Month 6

Absolute Manifest Cylinder (MRCYL) Compared Between the Two Study Groups, LAL and Control

时间窗: Postop Month 6

次要结局

  • Rate of Endothelial Cell Density Loss(Postop Month 6)
  • Rate of Retinal Findings(Postop Month 6)

研究者

发起方
RxSight, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (27)

Loading locations...

相似试验